Gil, D W <br/><br/>
Pirenzepine distinguishes between muscarinic receptor-mediated phosphoinositide breakdown and inhibition of adenylate cyclase.  [electronic resource] 

 -  The Journal of pharmacology and experimental therapeutics  Mar 1985 
 - 608-16 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S. 
<br/><br/><label>ISSN: </label>0022-3565 
<br/><br/><label>Subjects--Topical Terms: </label><br/>(4-(m-Chlorophenylcarbamoyloxy)-2-butynyl)trimethylammonium Chloride--pharmacology<br/>Acetylcholine--pharmacology<br/>Adenylyl Cyclase Inhibitors<br/>Animals<br/>Atropine--pharmacology<br/>Benzodiazepinones--pharmacology<br/>Brain--metabolism<br/>Carbachol--pharmacology<br/>In Vitro Techniques<br/>Inositol--analogs & derivatives<br/>Inositol Phosphates<br/>Male<br/>Myocardium--metabolism<br/>Oxotremorine--pharmacology<br/>Parotid Gland--metabolism<br/>Phosphatidylinositols--metabolism<br/>Pirenzepine<br/>Quinuclidinyl Benzilate--metabolism<br/>Radioligand Assay<br/>Rats<br/>Rats, Inbred Strains<br/>Receptors, Muscarinic--drug effects